- |||||||||| baxdrostat (CIN-107) / AstraZeneca
Enrollment change, Trial completion date, Trial primary completion date: spark-PA: A Study of CIN-107 in Adults With Primary Aldosteronism (clinicaltrials.gov) - Jul 20, 2022
P2, N=18, Recruiting,
N=96 --> 18 | Trial completion date: Mar 2022 --> Apr 2023 | Trial primary completion date: Feb 2022 --> Mar 2023
- |||||||||| baxdrostat (CIN-107) / CinCor Pharma
Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107 (Research Gateway 5) - Jun 15, 2022 - Abstract #ESC2022ESC_3682;
Oral administration of CIN-107 was safe and well tolerated in all subjects and resulted in dose-dependent increases in plasma CIN-107 with a half-life that supports once-daily dosing. The dose-dependent decrease in plasma aldosterone and lack of effect on cortisol demonstrate the selective blockade of aldosterone synthase and support continued study in ongoing phase 2 clinical trials evaluating the efficacy and safety of CIN-107 for treatment-resistant or uncontrolled hypertension and primary aldosteronism.
- |||||||||| baxdrostat (CIN-107) / AstraZeneca
Enrollment closed: A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) (clinicaltrials.gov) - May 11, 2022
P2, N=348, Active, not recruiting,
The dose-dependent decrease in plasma aldosterone and lack of effect on cortisol demonstrate the selective blockade of aldosterone synthase and support continued study in ongoing phase 2 clinical trials evaluating the efficacy and safety of CIN-107 for treatment-resistant or uncontrolled hypertension and primary aldosteronism. Recruiting --> Active, not recruiting
- |||||||||| baxdrostat (CIN-107) / AstraZeneca
Trial completion date, Trial primary completion date: A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) (clinicaltrials.gov) - Mar 29, 2022
P2, N=348, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Oct 2022 --> Jun 2022 | Trial primary completion date: Oct 2022 --> Jun 2022
- |||||||||| baxdrostat (CIN-107) / AstraZeneca
Trial completion date, Trial primary completion date: A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN) (clinicaltrials.gov) - Aug 25, 2021
P2, N=348, Recruiting,
Trial completion date: Oct 2022 --> Jun 2022 | Trial primary completion date: Oct 2022 --> Jun 2022 Trial completion date: Dec 2021 --> Oct 2022 | Trial primary completion date: Dec 2021 --> Oct 2022
|
